MiMedx Group (MDXG) Competitors $6.80 +0.03 (+0.44%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$6.80 0.00 (-0.07%) As of 04/15/2025 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MDXG vs. BLCO, SLNO, IRTC, PRCT, NVST, TMDX, LIVN, ENOV, NVCR, and LMATShould you be buying MiMedx Group stock or one of its competitors? The main competitors of MiMedx Group include Bausch + Lomb (BLCO), Soleno Therapeutics (SLNO), iRhythm Technologies (IRTC), PROCEPT BioRobotics (PRCT), Envista (NVST), TransMedics Group (TMDX), LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry. MiMedx Group vs. Bausch + Lomb Soleno Therapeutics iRhythm Technologies PROCEPT BioRobotics Envista TransMedics Group LivaNova Enovis NovoCure LeMaitre Vascular MiMedx Group (NASDAQ:MDXG) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership. Does the media refer more to MDXG or BLCO? In the previous week, MiMedx Group had 8 more articles in the media than Bausch + Lomb. MarketBeat recorded 12 mentions for MiMedx Group and 4 mentions for Bausch + Lomb. MiMedx Group's average media sentiment score of 1.31 beat Bausch + Lomb's score of 0.64 indicating that MiMedx Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch + Lomb 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, MDXG or BLCO? MiMedx Group has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiMedx Group$348.88M2.83$58.23M$0.2823.96Bausch + Lomb$4.79B0.87-$317M-$0.91-13.03 Does the MarketBeat Community believe in MDXG or BLCO? MiMedx Group received 8 more outperform votes than Bausch + Lomb when rated by MarketBeat users. Likewise, 82.46% of users gave MiMedx Group an outperform vote while only 41.49% of users gave Bausch + Lomb an outperform vote. CompanyUnderperformOutperformMiMedx GroupOutperform Votes4782.46% Underperform Votes1017.54%Bausch + LombOutperform Votes3941.49% Underperform Votes5558.51% Do institutionals & insiders have more ownership in MDXG or BLCO? 79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 1.3% of MiMedx Group shares are owned by insiders. Comparatively, 0.2% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, MDXG or BLCO? MiMedx Group has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Do analysts rate MDXG or BLCO? MiMedx Group currently has a consensus price target of $12.00, indicating a potential upside of 78.84%. Bausch + Lomb has a consensus price target of $18.82, indicating a potential upside of 58.67%. Given MiMedx Group's stronger consensus rating and higher possible upside, research analysts plainly believe MiMedx Group is more favorable than Bausch + Lomb.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiMedx Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Bausch + Lomb 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25 Is MDXG or BLCO more profitable? MiMedx Group has a net margin of 23.86% compared to Bausch + Lomb's net margin of -6.62%. MiMedx Group's return on equity of 26.21% beat Bausch + Lomb's return on equity.Company Net Margins Return on Equity Return on Assets MiMedx Group23.86% 26.21% 18.15% Bausch + Lomb -6.62%3.35%1.66% SummaryMiMedx Group beats Bausch + Lomb on 16 of the 18 factors compared between the two stocks. Remove Ads Get MiMedx Group News Delivered to You Automatically Sign up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDXG vs. The Competition Export to ExcelMetricMiMedx GroupSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$988.83M$4.07B$5.32B$7.56BDividend YieldN/A39.50%5.11%4.33%P/E Ratio12.2027.6221.7717.81Price / Sales2.8347.55378.2693.59Price / Cash41.7551.0838.1534.64Price / Book6.855.826.443.99Net Income$58.23M$67.09M$3.20B$247.23M7 Day Performance-2.19%5.89%6.42%7.24%1 Month Performance-15.28%-3.03%-8.66%-6.26%1 Year Performance5.67%14.50%10.27%-0.18% MiMedx Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDXGMiMedx Group3.1856 of 5 stars$6.80+0.4%$12.00+76.5%+7.1%$1.00B$348.88M12.36870Positive NewsGap DownBLCOBausch + Lomb3.8719 of 5 stars$11.86-2.1%$18.82+58.7%-16.5%$4.18B$4.79B-13.0312,500Gap DownSLNOSoleno Therapeutics4.7804 of 5 stars$69.64+3.2%$99.63+43.1%+82.4%$3.19BN/A-20.9830Analyst ForecastGap DownHigh Trading VolumeIRTCiRhythm Technologies0.9177 of 5 stars$100.17-0.2%$119.73+19.5%-8.0%$3.15B$591.84M-27.521,790Positive NewsPRCTPROCEPT BioRobotics2.3993 of 5 stars$50.83-0.8%$94.29+85.5%+4.6%$2.79B$224.50M-26.07430Positive NewsGap DownHigh Trading VolumeNVSTEnvista4.3811 of 5 stars$15.27-1.4%$20.18+32.2%-21.0%$2.63B$2.51B-2.3512,700Analyst ForecastAnalyst RevisionNews CoveragePositive NewsGap DownTMDXTransMedics Group2.7688 of 5 stars$69.15+2.2%$122.70+77.4%-5.1%$2.33B$441.54M73.56210LIVNLivaNova3.555 of 5 stars$35.40-1.5%$61.17+72.8%-34.8%$1.92B$1.25B84.292,900News CoveragePositive NewsGap DownHigh Trading VolumeENOVEnovis2.2051 of 5 stars$32.41-0.4%$58.50+80.5%-44.7%$1.85B$2.11B-14.806,800Gap DownNVCRNovoCure3.3286 of 5 stars$16.61+0.7%$35.80+115.5%+29.4%$1.83B$605.22M-11.861,320LMATLeMaitre Vascular3.0974 of 5 stars$79.39-0.5%$95.25+20.0%+31.3%$1.79B$219.86M43.38490News CoveragePositive NewsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Bausch + Lomb Alternatives Soleno Therapeutics Alternatives iRhythm Technologies Alternatives PROCEPT BioRobotics Alternatives Envista Alternatives TransMedics Group Alternatives LivaNova Alternatives Enovis Alternatives NovoCure Alternatives LeMaitre Vascular Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDXG) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiMedx Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiMedx Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MDXG Stock Free MDXG Stock Alerts